FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
- Details
- Category: FDA

Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
- Details
- Category: FDA

AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
- Details
- Category: EMA

In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc expert group.
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
- Details
- Category: EMA

EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
- Details
- Category: EMA

EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU
- Details
- Category: EMA

After a thorough evaluation, EMA’s human medicines committee (CHMP) concluded by consensus that the data on the vaccine were robust and met the criteria for efficacy, safety and quality.
EMA starts rolling review of the Sputnik V COVID-19 vaccine
- Details
- Category: EMA

More Pharma News ...
- FDA issues Emergency Use Authorization for third COVID-19 vaccine
- FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
- EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
- FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
- Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
- FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
- EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2